Literature DB >> 20070408

Expression and regulation of interleukin-33 in human monocytes.

Christopher J Nile1, Emma Barksby, Paiboon Jitprasertwong, Philip M Preshaw, John J Taylor.   

Abstract

Interleukin-33 (IL-33) is an IL-1 family cytokine that has a role in regulating T helper type 2 cytokines and mast cell development. Expression of IL-33 is also associated with chronic inflammatory conditions such as rheumatoid arthritis. However, there is little information regarding IL-33 in myeloid cell immune responses, which are important in immunity and inflammation. We therefore investigated the expression, intracellular location and regulation of myeloid cell IL-33 by lipopolysaccharide (LPS) from Escherichia coli and the periodontal pathogen Porphyromonas gingivalis. We detected IL-33 messenger RNA in the human promonocytic cell line THP-1, in monocytes derived from these cells and in primary human monocytes. However, IL-33 was not expressed in primary monocyte-derived dendritic cells. Stimulation of monocytes with E. coli LPS (Toll-like receptor 4 agonist) and LPS from P. gingivalis (Toll-like receptor 2 agonist) up-regulated IL-33 at both the messenger RNA and protein levels but IL-1beta and tumour necrosis factor-alpha had no effect. The IL-33 protein was mainly found in the cytoplasm of monocytes with no evidence of nuclear translocation in stimulated cells. Furthermore, no IL-33 secretion was detected after stimulation with LPS and/or ATP. These data indicate that the function, if any, of IL-33 in activated monocytes is primarily intracellular. Interestingly, immunofluorescence analysis indicated that IL-33 was sequestered in the nucleus of monocytes undergoing apoptosis but released into the extracellular milieu by LPS-stimulated cells in which necrosis had been induced by freeze-thawing. Therefore, this endorses the view that IL-33 may function as an 'alarmin' and have a role in signalling cellular damage and inflammatory disease pathogenesis through release from damaged or necrotic cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20070408      PMCID: PMC2878462          DOI: 10.1111/j.1365-2567.2009.03221.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules.

Authors:  Espen S Baekkevold; Myriam Roussigné; Takeshi Yamanaka; Finn-Eirik Johansen; Frode L Jahnsen; François Amalric; Per Brandtzaeg; Monique Erard; Guttorm Haraldsen; Jean-Philippe Girard
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

2.  The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1.

Authors:  Corinne Cayrol; Jean-Philippe Girard
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

3.  VIP Inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes.

Authors:  N Foster; J Cheetham; J J Taylor; P M Preshaw
Journal:  J Dent Res       Date:  2005-11       Impact factor: 6.116

Review 4.  T1/ST2--an IL-1 receptor-like modulator of immune responses.

Authors:  Vladimir Trajkovic; Matthew J Sweet; Damo Xu
Journal:  Cytokine Growth Factor Rev       Date:  2004 Apr-Jun       Impact factor: 7.638

5.  HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Authors:  Patrizia Rovere-Querini; Annalisa Capobianco; Paola Scaffidi; Barbara Valentinis; Federica Catalanotti; Marta Giazzon; Ingrid E Dumitriu; Susanne Müller; Matteo Iannacone; Catia Traversari; Marco E Bianchi; Angelo A Manfredi
Journal:  EMBO Rep       Date:  2004-07-23       Impact factor: 8.807

6.  Differential expression of immunoregulatory genes in monocytes in response to Porphyromonas gingivalis and Escherichia coli lipopolysaccharide.

Authors:  H E Barksby; C J Nile; K M Jaedicke; J J Taylor; P M Preshaw
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

7.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.

Authors:  Paola Scaffidi; Tom Misteli; Marco E Bianchi
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

8.  An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor.

Authors:  Maho Suzukawa; Motoyasu Iikura; Rikiya Koketsu; Hiroyuki Nagase; Chise Tamura; Akiko Komiya; Susumu Nakae; Kouji Matsushima; Ken Ohta; Kazuhiko Yamamoto; Masao Yamaguchi
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

9.  Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis.

Authors:  Gaby Palmer; Dominique Talabot-Ayer; Céline Lamacchia; Dean Toy; Christian A Seemayer; Sébastien Viatte; Axel Finckh; Dirk E Smith; Cem Gabay
Journal:  Arthritis Rheum       Date:  2009-03

10.  The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?

Authors:  Christine Moussion; Nathalie Ortega; Jean-Philippe Girard
Journal:  PLoS One       Date:  2008-10-06       Impact factor: 3.240

View more
  46 in total

Review 1.  Interleukin-33 biology with potential insights into human diseases.

Authors:  Gaby Palmer; Cem Gabay
Journal:  Nat Rev Rheumatol       Date:  2011-04-26       Impact factor: 20.543

Review 2.  IL-33 family members and asthma - bridging innate and adaptive immune responses.

Authors:  Clare M Lloyd
Journal:  Curr Opin Immunol       Date:  2010-11-09       Impact factor: 7.486

3.  Dynamic role of epithelium-derived cytokines in asthma.

Authors:  Kathleen R Bartemes; Hirohito Kita
Journal:  Clin Immunol       Date:  2012-03-20       Impact factor: 3.969

4.  Distinctive cytokine, chemokine, and antibody responses in Echinococcus multilocularis-infected patients with cured, stable, or progressive disease.

Authors:  Xiangsheng Huang; Beate Grüner; Christian J Lechner; Peter Kern; Peter T Soboslay
Journal:  Med Microbiol Immunol       Date:  2014-02-09       Impact factor: 3.402

5.  Interleukin-33 contributes to disease severity in Dengue virus infection in mice.

Authors:  Rafael E Marques; Anne-Gaëlle Besnard; Isabelle Maillet; Caio T Fagundes; Danielle G Souza; Bernhard Ryffel; Mauro M Teixeira; Foo Y Liew; Rodrigo Guabiraba
Journal:  Immunology       Date:  2018-09-10       Impact factor: 7.397

6.  Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients.

Authors:  George P Christophi; Ross C Gruber; Michael Panos; Rebecca L Christophi; Burk Jubelt; Paul T Massa
Journal:  Clin Immunol       Date:  2011-12-02       Impact factor: 3.969

7.  Interleukin-33 in the human placenta.

Authors:  Vanessa Topping; Roberto Romero; Nandor Gabor Than; Adi L Tarca; Zhonghui Xu; Sun Young Kim; Bing Wang; Lami Yeo; Chong Jai Kim; Sonia S Hassan; Jung-Sun Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2012-11-23

8.  Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway.

Authors:  Lei Sun; Ziyan Zhu; Ni Cheng; Qian Yan; Richard D Ye
Journal:  Eur J Immunol       Date:  2014-05-22       Impact factor: 5.532

9.  Anti-interleukin-33 inhibits cigarette smoke-induced lung inflammation in mice.

Authors:  Chuan Qiu; Yan Li; Mingcai Li; Min Li; Xiaojin Liu; Charles McSharry; Damo Xu
Journal:  Immunology       Date:  2013-01       Impact factor: 7.397

10.  Increased levels of interleukin-33 in gingival crevicular fluids of patients with chronic periodontitis.

Authors:  Mehmet Sağlam; Serhat Köseoğlu; Cüneyt Asım Aral; Levent Savran; Tuğba Pekbağrıyanık; Ayşe Çetinkaya
Journal:  Odontology       Date:  2016-06-30       Impact factor: 2.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.